Palo Alto Investors LLC raised its holdings in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 1.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,467,575 shares of the company’s stock after purchasing an additional 61,100 shares during the quarter. Karyopharm Therapeutics makes up 1.5% of Palo Alto Investors LLC’s holdings, making the stock its 18th biggest position. Palo Alto Investors LLC owned about 7.36% of Karyopharm Therapeutics worth $31,382,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in KPTI. Teachers Advisors LLC lifted its holdings in Karyopharm Therapeutics by 15.0% during the 4th quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock valued at $389,000 after purchasing an additional 5,419 shares during the last quarter. Nationwide Fund Advisors lifted its holdings in Karyopharm Therapeutics by 175.8% during the 1st quarter. Nationwide Fund Advisors now owns 56,527 shares of the company’s stock valued at $726,000 after purchasing an additional 36,031 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Karyopharm Therapeutics by 103.9% during the 1st quarter. Russell Investments Group Ltd. now owns 74,882 shares of the company’s stock valued at $962,000 after purchasing an additional 38,158 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Karyopharm Therapeutics by 114.6% during the 1st quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock valued at $560,000 after purchasing an additional 23,284 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Karyopharm Therapeutics by 61.7% during the 1st quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock valued at $2,332,000 after purchasing an additional 69,315 shares during the last quarter. 58.97% of the stock is owned by institutional investors and hedge funds.

KPTI has been the subject of several research reports. Canaccord Genuity set a $18.00 price target on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 8th. Jefferies Group LLC reiterated a “buy” rating and set a $19.00 price objective (up previously from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Thursday, July 6th. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 24th. Finally, BidaskClub upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $15.67.

In other news, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $31,702.00. Following the transaction, the director now owns 2,882 shares of the company’s stock, valued at approximately $31,702. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 10,695 shares of company stock worth $118,950 in the last ninety days. Insiders own 14.71% of the company’s stock.

Karyopharm Therapeutics Inc. (NASDAQ KPTI) traded down 1.37% on Thursday, reaching $11.51. The company’s stock had a trading volume of 37,694 shares. The firm’s market cap is $542.56 million. The firm has a 50 day moving average of $10.22 and a 200 day moving average of $9.86. Karyopharm Therapeutics Inc. has a 12 month low of $6.27 and a 12 month high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, meeting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. During the same quarter in the previous year, the firm posted ($0.84) EPS. Karyopharm Therapeutics’s revenue was down 95.0% compared to the same quarter last year. Analysts anticipate that Karyopharm Therapeutics Inc. will post ($2.67) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Palo Alto Investors LLC Increases Holdings in Karyopharm Therapeutics Inc. (KPTI)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/05/palo-alto-investors-llc-increases-holdings-in-karyopharm-therapeutics-inc-kpti.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.